RG
AVIR icon

Redmile Group’s Atea Pharmaceuticals AVIR Stock Holding History

Redmile Group’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-237,360
Closed -$5.1M – 77
2021
Q2 		$5.1M Sell
237,360
-920,722
-80% -$27.7M 0.08% 80
2021
Q1 		$71.5M Sell
1,158,082
-1,073,628
-48% -$72.5M 1.01% 38
2020
Q4 		$93.2M Buy
+2,231,710
New +$71.9M 1.13% 28

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Redmile Group's AVIR Position: Q3 2021 in Review

Redmile Group sold out of Atea Pharmaceuticals (AVIR) in Q3 2021, closing a stake of 237,360 shares — an estimated $5.1M sold.

Redmile Group first reported a position in AVIR in Q4 2020 and held it in 3 quarters. The position peaked at $93.2M in Q4 2020. 142 funds tracked by Wall St. Rank hold AVIR as of Q3 2021.

  • Redmile Group reported no remaining Atea Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Redmile Group sold 237,360 Atea Pharmaceuticals shares in Q3 2021, an estimated $5.1M.
  • Redmile Group first reported a position in Atea Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • Redmile Group's Atea Pharmaceuticals position peaked at $93.2M in Q4 2020.
  • 142 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2021.

Based on Redmile Group's 13F filing for Q3 2021, filed 15 Nov 2021.